07:00 , May 5, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: GD3 ganglioside; ST8 α-N-acetyl-neuraminide α-2,8-sialyltransferase 1 (ST8SIA1); prominin 1 (PROM1; CD133)

Cancer INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting GD3 ganglioside or its synthetic enzyme ST8SIA1 could help treat glioblastoma multiforme (GBM). In patients, tumor levels of GD3 ganglioside and ST8SIA1...
07:00 , Mar 18, 2013 |  BioCentury  |  Strategy

Japan's biggest biotech

Japanese pharmaceutical companies have historically been thought of as stodgy, insular and opaque, but that is changing fast. One year into the job, Kyowa Hakko Kirin Co. Ltd. 's CEO is building his company along...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Clinical News

ABT-806: Phase I started

Abbott began a 6-month, open-label, dose-ranging Phase I trial to evaluate IV ABT-806 in up to 30 patients. Abbott has rights to the compound from Life Science under a 2008 deal (see BioCentury, Nov. 24,...
08:00 , Nov 18, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Fibroblast activation protein (FAP) Mouse studies suggest that eliminating FAP-expressing cells in the tumor microenvironment could improve responses to cancer immunotherapy. In transgenic mice...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Company News

Life Science Pharmaceuticals, Abbott deal

Life Science granted Abbott exclusive, worldwide rights to develop and commercialize ch806 to treat cancer and other indications, including psoriasis. Abbott did not disclose its plans for the chimeric antibody targeting a tumor-specific epitope on...
07:00 , Mar 19, 2007 |  BC Week In Review  |  Company News

Life Science Pharmaceuticals, Kyowa Hakko Kogyo Co. Ltd. deal

Life Science received exclusive worldwide rights to develop and market Kyowa's KW-2871 to treat malignant melanoma. Life Science plans to start a Phase II trial of the chimeric MAb against the GD3 antigen by early...
01:21 , Mar 16, 2007 |  BC Extra  |  Company News

Life Science in-licenses Kyowa's KW-2871

Kyowa Hakko Kogyo (Tokyo:4151) granted Life Science Pharmaceuticals (Greenwich, Conn.) exclusive worldwide rights to develop and market KW-2871 to treat malignant melanoma. Life Science plans to start a Phase II trial of the chimeric MAb...
07:00 , Mar 12, 2007 |  BC Week In Review  |  Clinical News

Ch806: Phase I data

In a dose-escalation, Australian Phase I trial in 8 cancer patients, ch806 showed tumor-specific targeting with no evidence of normal tissue uptake and no significant toxicity. Doses of up to 40 mg/m 2 were well...
08:00 , Feb 19, 2007 |  BC Week In Review  |  Company News

American Life Science Pharmaceuticals Inc. management update

American Life Science Pharmaceuticals Inc. , San Diego, Calif.   Business: Neurology   Hired: Michael Pierschbacher as president, CEO and a director, formerly SVP of R&D at Integra LifeSciences Holdings Corp. ; he replaces CEO...
07:00 , Jun 5, 2006 |  BC Week In Review  |  Company News

Life Science Pharmaceuticals, Ludwig Institute for Cancer Research deal

The institute granted Life Science exclusive worldwide rights to develop and commercialize three MAbs for cancer and autoimmune diseases. The antibodies target epidermal growth factor receptor (EGFR) , fibroblast activating protein, and an undisclosed epitope...